Abeona Therapeutics

September 18, 2018September 18, 2018

Abeona to Begin Its Phase 1/2 Gene Therapy Trial for Sanfilippo Type B in Spain

News

Abeona Therapeutics will begin a Phase 1/2 clinical trial in Spain testing the company’s investigational gene therapy ABO-101 in patients with Sanfilippo syndrome type B. The company has received approval from the ... Read more

June 5, 2018June 5, 2018

Abeona Therapeutics Opens New Manufacturing Facility in Ohio for Its Gene, Cell Therapies

News

Abeona Therapeutics has announced the opening of The Elisa Linton Center for Rare Disease Therapies, a commercial manufacturing facility for advanced gene and cell therapies in Cleveland, Ohio. The new GMP ... Read more

May 24, 2018May 24, 2018

ABO-102 Gene Therapy for Type A Patients Continues to Show Key and Durable Benefits in Trial, Abeona Reports

News

Sanfilippo syndrome type A patients treated with the gene therapy candidate ABO-102 continue to show robust and sustained clinical improvements in a Phase 1/2 trial, its developer, Abeona Therapeutics, reports. ... Read more

April 24, 2018April 24, 2018

FDA Grants RMAT Designation to Abeona’s ABO-102 for Sanfilippo Syndrome Type A

News

The U.S. Food and Drug Administration granted its regenerative medicine advanced therapy (RMAT) designation to Abeona Therapeutics‘ investigative gene therapy ABO-102, under development for the treatment of Sanfilippo syndrome type A. ... Read more

February 15, 2018February 15, 2018

Abeona Reports Positive Data from Clinical Trial of ABO-102 for Sanfilippo Type A

News

Abeona Therapeutics announced that ABO-102 (AAV-SGSH), an investigational therapy for Sanfilippo syndrome type A (MPS IIIA), demonstrated significant and durable clinical effects at various time points in a clinical trial. Results ... Read more

February 8, 2018February 8, 2018

Preliminary Results Show Promise in Clinical Trial of ABO-101 for Sanfilippo Syndrome Type B

News

Abeona Therapeutics has reported preliminary 30-day safety and efficacy results from the first patient dosed in the company’s ongoing Phase 1/2 trial of a single treatment gene therapy candidate ... Read more

Pin It on Pinterest